Godavari Biorefineries Ltd., through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China’s patent and trademark office, for its novel anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE.

This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer.

“Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,” said Dr. Sangeeta Srivastava, Executive Director, Godavari Biorefineries Ltd. “This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide,” she added.

Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company’s clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its focus in translational research that addresses some of the world’s most urgent health challenges.